2023 ESC Guidelines for the management of cardiomyopathies: Developed by the task force on the management of cardiomyopathies of the European Society of …

E Arbelo, A Protonotarios, JR Gimeno… - European heart …, 2023 - academic.oup.com
• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on …

PA Heidenreich, B Bozkurt, D Aguilar, LA Allen… - Journal of the American …, 2022 - jacc.org
Abstract Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and …

Authors/Task Force Members:… - European journal of …, 2022 - Wiley Online Library
Abstract Document Reviewers: Rudolf A. de Boer (CPG Review Coordinator)(Netherlands),
P. Christian Schulze (CPG Review Coordinator)(Germany), Magdy Abdelhamid (Egypt) …

2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: Developed by the Task Force on cardiac pacing and cardiac resynchronization …

M Glikson, JC Nielsen, MB Kronborg, Y Michowitz… - EP …, 2022 - academic.oup.com
for digital applications (smartphones, etc.). These versions are abridged and thus, for more
detailed information, the user should always access to the full text version of the guidelines …

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and …

TA McDonagh, M Metra, M Adamo… - European heart …, 2021 - academic.oup.com
The aim of this ESC Guideline is to help health professionals manage people with heart
failure (HF) according to the best available evidence. Fortunately, we now have a wealth of …

A research agenda for ageing in China in the 21st century: Focusing on basic and translational research, long-term care, policy and social networks

EF Fang, C Xie, JA Schenkel, C Wu, Q Long… - Ageing research …, 2020 - Elsevier
One of the key issues facing public healthcare is the global trend of an increasingly ageing
society which continues to present policy makers and caregivers with formidable healthcare …

JCS/JHRS 2019 guideline on non-pharmacotherapy of cardiac arrhythmias

A Nogami, T Kurita, H Abe, K Ando, T Ishikawa… - Circulation …, 2021 - jstage.jst.go.jp
Pacemaker treatment for bradyarrhythmia was first approved for national health insurance
coverage in Japan in 1974, and its use rapidly became widespread thereafter …

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes …

F Cosentino, PJ Grant, V Aboyans… - European heart …, 2020 - academic.oup.com
Health professionals are encouraged to take the Guidelines fully into account when
exercising their clinical judgment, as well as in the determination and the implementation of …

Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of …

J Bauersachs, T König, P van der Meer… - European journal of …, 2019 - Wiley Online Library
Peripartum cardiomyopathy (PPCM) is a potentially life‐threatening condition typically
presenting as heart failure with reduced ejection fraction (HFrEF) in the last month of …

Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology

PM Seferović, MC Petrie, GS Filippatos… - European journal of …, 2018 - Wiley Online Library
The coexistence of type 2 diabetes mellitus (T2DM) and heart failure (HF), either with
reduced (HFrEF) or preserved ejection fraction (HFpEF), is frequent (30–40% of patients) …